

October 12, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated October 12, 2018 titled "Zydus receives tentative approval from the USFDA for Linagliptin and Metformin Hydrochloride Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for, 
UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives tentative approval from the USFDA for Linagliptin and Metformin Hydrochloride Tablets

Ahmedabad, 12 October, 2018

Zydus Cadila has received the tentative approval from the USFDA to market Linagliptin and Metformin Hydrochloride Tablets (US RLD – Jentaducto[®] Tablets), 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1,000 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. It is used alongwith diet and exercise to improve control of blood sugar levels in adults with type 2 diabetes mellitus.

The group now has 221 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
